Currently Synthase has raised NZD $1.2M through a $1.4M convertible note. It plans to commence a series A in September 2023.
Our shareholding base includes the Board and management; private individuals; three of New Zealand’s principal angel investment entities - Enterprise Angels, Ice Angels and Marlborough Angels; and the New Zealand Government through its specialist, hi-tech investment fund, NZ Growth Capital Partners. We have also continued to receive significant backing from the NZ Government’s hi-tech support agency, Callaghan Innovation. Interested investment parties may contact Mark Backhaus (Chairman – m.backhaus@synthasebiotech.com ).
Copyright © | View Desktop Version